



ANCA VASCULITIS SUMMIT

15 DEC.
20:00 - 22:30
KSA TIME **2021**

The event will be held in the following venues:

- **Jeddah:** Crowne Plaza Jeddah
- **Riyadh:** Marriott Hotel
- **Dammam:** Kempinski Al Othman Hotel Al Khobar

Attendees who will not be able to join us in person can attend the event online.

[Join the Meeting](#)

This Event is organized by GSK in collaboration with Saudi Society of Rheumatology and intended for healthcare professionals in Saudi Arabia only. Trademarks are owned by or licensed to the GSK group of companies. Copyright© GlaxoSmithKline 2021. All rights reserved.

Chairpersons



Dr. Hanan Al Rayes, MD

President of Saudi Society for Rheumatology, Deputy Director Medicine Department, Director of Rheumatology Fellowship, Prince Sultan Military Medical City



Dr. Ramiz Alswailem

Consultant Rheumatologist, EX-President of the Saudi Society for Rheumatology



Dr. Hussein M. Halabi, MD

Director of Academic and Training Affairs, KFSH&RC, Jeddah

Speakers



Dr. Amel Al Harthi

Consultant Rheumatology
Security Forces hospital Riyadh



Dr. Sadeem Alfuraih

Senior Registrar KFSH, Riyadh



Dr. Abdullah Almutlaq MD, MBA

Consultant Rheumatology, Deputy Chairman, Department of Medicine, King Faisal Specialist Hospital and Research Center



Dr. Abdulrahman Albeity

Dr. Abdulrahman Albeity is an Assistant Consultant Rheumatologist at King Faisal Specialist Hospital and Research Center, Jeddah.



Issra Molla

Consultant Rheumatology
King Faisal Specialist Hospital Jeddah



Dr. Riyadh Al-Lehebi MD, FRCPC, DABIM

Consultant, Pulmonary, Asthma and Sleep Medicine Lead, Severe Asthma Clinical Program Saudi Lead, International Severe Asthma Registry, King Fahad Medical City, Riyadh

Agenda

Time	Topic	Speaker
20:00 - 20:05	Introduction and Welcoming Message	Dr. Hanan Al Rayes
Chairperson: Dr. Ramiz Alswailem - Dr. Hussein M. Halabi		
20:05 - 20:25	Disease Landscape and Differential Diagnosis of ANCA Vasculitis (ACR Diagnostic Criteria)	Dr. Amel Al Harthi
20:25 - 20:45	Challenging Cases in Vasculitis I	Dr. Sadeem Alfuraih
20:45 - 21:05	Update in Treatment on ANCA Vasculitis	Dr. Abdullah Almutlaq
21:05 - 21:15	Discussion	
Chairperson: Dr. Hussein M. Halabi - Dr. Ramiz Alswailem		
21:15 - 21:35	Challenging Cases in Vasculitis II	Dr. Abdulrahman Albeity
21:35 - 21:50	Management of Eosinophilic Granulomatous Vasculitis	Issra Molla
21:50 - 22:10	EGPA Comorbidities Current Management (Severe Asthma)	Dr. Riyadh Al-Lehebi
22:10 - 22:20	Discussion	
22:20 - 22:30	Closing Remarks	Dr. Hanan Al Rayes

For medical information, please contact GlaxoSmithKline via gcc.medinfo@gsk.com

To report an adverse event/s associated with the use of GSK product/s, please contact us via Saudi.safety@gsk.com.

To report a quality-related product complaint/s associated with the use of GSK product/s, please contact us via Gulf-KSA.Product-Complaints@gsk.com

This message is for the use of a Registered Medical Practitioner or a Hospital or a Laboratory only. You are receiving this email as we have your details as a healthcare professional. If you do not wish to receive these emails in future or unsubscribe, please [click below](#). E-mail programs can consider these messages as junk mail and may automatically put them in your bulk or junk folder. To ensure the e-mails you've requested are delivered to your inbox, add our e-mail address to your address book. Please do not reply to this message. These emails are not monitored and do not accept replies.

For more information, please refer to the prescribing information or contact GlaxoSmithKline gcc.medinfo@gsk.com. To report an adverse event/s associated with the use of GSK product/s, please refer to the saudi.safety@gsk.com. To report the quality related product complaint/s associated with the use of GSK product/s, please contact us via Gulf-KSA.Product-Complaints@gsk.com.

About your privacy: GSK may monitor our technology tools and services (including email, phone, and other communications sent to and from GSK) in order to maintain the security of systems, and to protect our staff, customers and business partners from cyber threats and loss of information.

Examples of these monitoring activities include checks for offensive materials, viruses and other malignant code, and unauthorized or unlawful activity. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws. You can learn about the information that we may process about you, and how we use your information, [click here](#).

You can also view our [terms of use](#).